Mona Ashiya Sells 202,146 Shares of Disc Medicine, Inc. (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) Director Mona Ashiya sold 202,146 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $54.29, for a total value of $10,974,506.34. Following the completion of the transaction, the director now owns 208,742 shares of the company's stock, valued at $11,332,603.18. The trade was a 49.20 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Mona Ashiya also recently made the following trade(s):

• On Wednesday, March 12th, Mona Ashiya sold 83,182 shares of Disc Medicine stock. The shares were sold at an average price of $54.45, for a total value of $4,529,259.90.

Disc Medicine Stock Performance

Shares of IRON stock traded down $1.39 during mid-day trading on Friday, hitting $51.02. The company's stock had a trading volume of 283,282 shares, compared to its average volume of 358,651. The company's fifty day simple moving average is $56.16 and its 200-day simple moving average is $56.01. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $68.86. The company has a market cap of $1.76 billion, a PE ratio of -12.82 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.08. On average, equities analysts anticipate that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.

Remove Ads

Analyst Upgrades and Downgrades

IRON has been the subject of a number of research reports. Scotiabank increased their price target on Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research note on Monday, March 3rd. Stifel Nicolaus raised their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. Morgan Stanley reaffirmed an "overweight" rating and set a $85.00 target price on shares of Disc Medicine in a research report on Friday, March 7th. Wedbush reaffirmed an "outperform" rating and set a $90.00 target price (up from $83.00) on shares of Disc Medicine in a research report on Tuesday, January 21st. Finally, HC Wainwright reaffirmed a "buy" rating and set a $118.00 target price on shares of Disc Medicine in a research report on Tuesday, January 21st. Ten research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $89.10.

Institutional Trading of Disc Medicine

Several large investors have recently made changes to their positions in IRON. Sterling Capital Management LLC grew its stake in shares of Disc Medicine by 798.4% in the 4th quarter. Sterling Capital Management LLC now owns 566 shares of the company's stock valued at $36,000 after buying an additional 503 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of Disc Medicine in the 4th quarter valued at about $40,000. Tower Research Capital LLC TRC grew its stake in shares of Disc Medicine by 47.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 825 shares of the company's stock valued at $52,000 after buying an additional 266 shares during the period. Quest Partners LLC acquired a new stake in shares of Disc Medicine in the 3rd quarter valued at about $131,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Disc Medicine in the 3rd quarter valued at about $146,000. 83.70% of the stock is currently owned by institutional investors and hedge funds.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.